Drug Profile
Research programme: siRNA therapeutics - Suzhou Ribo Life Sciences
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Suzhou Ribo Life Science
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Fibrosis; HIV infections; Liver cancer; Pancreatic cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Fibrosis in China (Parenteral)
- 28 Aug 2020 No recent reports of development identified for research development in HIV-infections in China (Parenteral)
- 28 Aug 2020 No recent reports of development identified for research development in Liver-cancer in China (Parenteral)